🇺🇸 FDA

Company profile · Sponsor

Mereo

Mereo BioPharma Group plc

MREO · NYSE biotech LONDON, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Mereo (MREO) is a biotech company. headquartered in LONDON, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker MREO
Exchange NYSE
Company type biotech
Headquarters LONDON, USA
SEC CIK 0001719714

Pipeline (24)

Search pipeline →

  1. Setrusumab

    Mereo

    Osteogenesis Imperfecta

    phase 3 mab active

    2 trials

  2. Active treatment with a high dose of BGS649

    Mereo

    Endometriosis

    phase 2 small molecule completed

    1 trial

  3. Alvelestat

    Mereo

    Covid19

    phase 2 small molecule completed

    1 trial

  4. Alvelestat (MPH966)

    Mereo

    Alpha-1 Antitrypsin Deficiency (AATD)

    phase 2 small molecule completed

    1 trial

  5. BCT197

    Mereo

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  6. BCT197

    Mereo

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  7. BCT197 Part A

    Mereo

    Acute Kidney Injury

    phase 2 small molecule terminated

    1 trial

  8. BGS649

    Mereo

    Pelvic Pain Associated With Refractory Endometriosis

    phase 2 small molecule terminated

    1 trial

  9. BGS649

    Mereo

    Hypogonadotropic Hypogonadism

    phase 2 small molecule completed

    2 trials

  10. BPS804

    Mereo

    Chronic-kidney Disease Stage 5D on Stable Hemodialysis

    phase 2 small molecule terminated

    1 trial

  11. BPS804

    Mereo

    Osteogenesis Imperfecta

    phase 2 small molecule terminated

    1 trial

  12. BPS804

    Mereo

    Hypophosphatasia

    phase 2 small molecule completed

    1 trial

  13. BPS804 20mg/Kg

    Mereo

    Osteopenia

    phase 2 small molecule completed

    1 trial

  14. Demcizumab

    Mereo

    Pancreatic Cancer

    phase 2 small molecule completed

    2 trials

  15. Etigilimab

    Mereo

    Solid Tumor, Adult

    phase 2 small molecule completed

    1 trial

  16. Investigational new drug company code: BGS649

    Mereo

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  17. MPH966

    Mereo

    Hematologic Malignancy

    phase 2 small molecule terminated

    1 trial

  18. Nivolumab

    Mereo

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  19. OMP-59R5

    Mereo

    Stage IV Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  20. OMP-59R5

    Mereo

    Stage IV Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  21. Pemetrexed

    Mereo

    Nonsquamous Nonsmall Cell Neoplasm of Lung

    phase 2 small molecule completed

    1 trial

  22. Placebo Oral Tablet

    Mereo

    Alpha 1-Antitrypsin Deficiency

    phase 2 small molecule completed

    1 trial

  23. setrusumab

    Mereo

    Osteogenesis Imperfecta, Type I

    phase 2 small molecule completed

    1 trial

  24. BCT197

    Mereo

    Interaction

    phase 1 small molecule completed

    2 trials

Patents (8)

Search patents →

  1. US 12173058

    Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11701341

    Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11512128

    VEGF/DLL4 binding agents and uses thereof

    Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11434204

    Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11339213

    Methods and compositions for treatment of cancer

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11234967

    Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11230596

    Methods for treatment of cancer comprising TIGIT-binding agents

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11136384

    Methods for treatment of cancer comprising TIGIT-binding agents

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Mereo?

Mereo (MREO) is a biotech company. headquartered in LONDON, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Mereo sponsor?

We track 24 ClinicalTrials.gov-linked programs for Mereo, including Setrusumab and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Mereo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.